PubRank

Neurodegenerative disease management (Neurodegener Dis Manag)

Journal PubWeight™ 76.79‹?›

Top papers

Rank Title Year PubWeight™‹?›
1 Activities of daily living: where do they fit in the diagnosis of Alzheimer's disease? 2012 1.08
2 Prevention of falls in Parkinson's disease: a review of fall risk factors and the role of physical interventions. 2014 0.97
3 Current and future potential of retinal optical coherence tomography in multiple sclerosis with and without optic neuritis. 2014 0.92
4 Depression versus dementia: is this construct still relevant? 2014 0.86
5 Should we disclose amyloid imaging results to cognitively normal individuals? 2013 0.86
6 Essential tremor is not a neurodegenerative disease. 2012 0.85
7 B cell-directed therapies in multiple sclerosis. 2016 0.85
8 Depression in the early stages of Huntington disease. 2011 0.85
9 Collaborative transdisciplinary team approach for dementia care. 2014 0.85
10 Appraisal of cognition in preclinical Alzheimer's disease: a conceptual review. 2012 0.85
11 When dementia progresses quickly: a practical approach to the diagnosis and management of rapidly progressive dementia. 2014 0.85
12 Cognitive interventions to enhance neural compensation in Huntington's disease. 2015 0.84
13 Nonmotor features in sex-linked dystonia parkinsonism. 2014 0.84
14 The sleep-wake cycle and Alzheimer's disease: what do we know? 2014 0.84
15 Using biomarkers to improve detection of Alzheimer's disease. 2011 0.84
16 Amyloid imaging, risk disclosure and Alzheimer's disease: ethical and practical issues. 2015 0.84
17 Review of 'the potential role of arterial stiffness in the pathogenesis of Alzheimer's disease'. 2015 0.83
18 Is neuropsychological rehabilitation effective in multiple sclerosis? 2014 0.83
19 The biomarker and therapeutic potential of miRNA in Alzheimer's disease. 2015 0.82
20 Retinal manifestations of Alzheimer's disease. 2014 0.82
21 A qualitative review of instrumental activities of daily living in dementia: what's cooking? 2014 0.82
22 Pathogenesis and treatment of vascular cognitive impairment. 2014 0.82
23 The impact of multiple sclerosis on family members: a review of the literature. 2014 0.82
24 Therapeutic potential of targeting metabotropic glutamate receptors for Parkinson's disease. 2012 0.81
25 The role of exercise in facilitating basal ganglia function in Parkinson's disease. 2011 0.80
26 Management of frontotemporal dementia: targeting symptom management in such a heterogeneous disease requires a wide range of therapeutic options. 2011 0.80
27 What role does tobacco smoking play in multiple sclerosis disability and mortality? A review of the evidence. 2015 0.80
28 Brain insulin resistance in Alzheimer's disease and its potential treatment with GLP-1 analogs. 2014 0.80
29 Frontotemporal dementia: diagnosis, deficits and management. 2014 0.79
30 Does the gut drive amyotrophic lateral sclerosis progress? 2015 0.79
31 New insights into Alzheimer's disease pathogenesis: the involvement of neuroligins in synaptic malfunction. 2015 0.79
32 Prevalence of multiple sclerosis symptoms across lifespan: data from the NARCOMS Registry. 2015 0.79
33 The role of oligodendroglial dysfunction in amyotrophic lateral sclerosis. 2014 0.79
34 Ultraviolet radiation, vitamin D and multiple sclerosis. 2015 0.79
35 Impulse control disorders in Parkinson's disease: background and update on prevention and management. 2012 0.79
36 Can microbiota research change our understanding of neurodegenerative diseases? 2016 0.78
37 How predictive of dementia are peripheral inflammatory markers in the elderly? 2012 0.78
38 Diagnosing dementia in adults with Down's syndrome. 2015 0.78
39 Aberrant RNA homeostasis in amyotrophic lateral sclerosis: potential for new therapeutic targets? 2014 0.78
40 Pesticides and Parkinson's disease: is it in your genes? 2014 0.78
41 Agitation and aggression in Alzheimer's disease: an update on pharmacological and psychosocial approaches to care. 2015 0.78
42 Breathing new life into treatment advances for respiratory failure in amyotrophic lateral sclerosis patients. 2014 0.78
43 Differential diagnosis of Huntington's disease: what the clinician should know. 2014 0.78
44 Remyelination in multiple sclerosis: what do we know and where are we going? 2015 0.78
45 Self-reports of executive functioning in multiple sclerosis: to trust or not to trust. 2014 0.77
46 Neuroimaging in Parkinson's disease: a future perspective. 2015 0.77
47 OPTIMIZING DIAGNOSIS AND MANANGEMENT IN MILD-TO-MODERATE ALZHEIMER'S DISEASE. 2012 0.77
48 Alemtuzumab in multiple sclerosis: an update. 2015 0.77
49 Nondopaminergic treatments for Parkinson's disease: current and future prospects. 2016 0.77
50 Behavioral treatments for speech in Parkinson's disease: meta-analyses and review of the literature. 2015 0.77
Next 50